Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3699-3706

  Stricker, Ingo ^a   Tzivras, Dimitri ^a   Nambiar, Sandeep ^a   Wulf, Juergen ^a   Liffers, Sven Thorsten ^a   Vogt, Markus ^a   Verdoodt, Berlinda ^a   Tannapfel, Andrea ^a   Mirmohammadsadegh, Alireza ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Gastroenteropancreatic neuroendocrine tumours; LINE1; Methylation pattern; Pyrosequencing

Indexed keywords

MEMBRANE PROTEIN; PROTEIN LONG INTERSPERSED ELEMENT 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; COLORECTAL TUMOR; CONTROLLED STUDY; CPG ISLAND; DNA ISOLATION; DUODENUM TUMOR; FEMALE; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEUM TUMOR; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PANCREATIC NEUROENDOCRINE TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN METHYLATION; PYROSEQUENCING; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; SMALL INTESTINE TUMOR; TUMOR LOCALIZATION; VATER PAPILLA CARCINOMA;

COHORT STUDIES; DNA METHYLATION; GASTROINTESTINAL NEOPLASMS; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; NEOPLASM GRADING; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PARAFFIN EMBEDDING;

EID: 84867026300     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kuiper P, Verspaget HW, Overbeek LI, Biemond I and Lamers CB: An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach. Neth J Med 69(1): 14-20, 2011.
2. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M and Modlin IM: The epidemiology of gastroenteropancreatic neuroendocrine tumours. Endocrinol Metab Clin North Am 40(1): 1-18, 2011.
3. Oberg K: Neuroendocrine tumours (NETs): Historical overview and epidemiology. Tumori 96(5): 797-801, 2010.
4. Klimstra DS, Modlin IR, Coppola D, Lloyd RV and Suster S: The pathologic classification of neuroendocrine tumours: A review of nomenclature, grading, and staging systems. Pancreas 39(6): 707-712, 2010.
5. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B; and all other Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS): TNM staging of foregut (neuro)endocrine tumours: a consensus proposal including a grading system. Virchows Arch 449(4): 395-401, 2006.
6. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY and Wiedenmann B: TNM staging of midgut and hindgut (neuro) endocrine tumours: A consensus proposal including a grading system. Virchows Arch 451(4): 757-762, 2007. (Pubitemid 47497934)
7. Tannapfel A and Wittekind C: The current TNM system for gastrointestinal tumours part II. Pathologe 31(5): 348-352, 2010. (in German).
8. Wittekind C: TNM 2010. What's new?. Pathologe Suppl 2: 153-160, 2010. (in German).
9. Wittekind C and Oberschmid B: TNM classification of malignant tumours 2010: General aspects and amendments in the general section. Pathologe 31(5): 333-334, 336-338, 2010. (in German).
10. Wittekind C and Tannapfel A: The current TNM system for gastrointestinal tumours part I. Pathologe 31(5): 344-347, 2010. (in German).
11. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G and Falconi M: Pancreatic endocrine tumours: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 23(6): 824-833, 2010.
12. Turaga KK and Kvols LK: Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumours. CA Cancer J Clin 61(2): 113-132, 2011.
13. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P and Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1): 61-72, 2008.
14. Leotlela PD, Jauch A, Holtgreve-Grez H and Thakker RV: Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 10(4): 437-450, 2003. (Pubitemid 38094880)
15. Tönnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W and Wiedenmann B: Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 48(4): 536-541, 2001. (Pubitemid 32234799)
16. Choi IS, Estecio MR, Nagano Y, Kim do H, White JA, Yao JC, Issa JP and Rashid A: Hypomethylation of LINE1 and Alu in well-differentiated neuroendocrine tumours (pancreatic endocrine tumours and carcinoid tumours). Mod Pathol 20(7): 802-810, 2007.
17. Rahman MM, Qian ZR, Wang EL, Yoshimoto K, Nakasono M, Sultana R, Yoshida T, Hayashi T, Haba R, Ishida M, Okabe H and Sano T: DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumours. Hum Pathol 41(8): 1069-1078, 2010.
18. Arnold CN, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, Schmitt-Gräff A, Boland CR, Arnold R and Blum HE: Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumours. Int J Cancer 123(7): 1556-1564, 2008.
19. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR and Rashid A: CpG island methylation in carcinoid and pancreatic endocrine tumours. Oncogene 22 (6): 924-934, 2003. (Pubitemid 36255828)
20. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann N, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, Gregory S, Hubbard T, Humphray S, Hunt A, Jones M, Lloyd C, McMurray A, Matthews L, Mercer S, Milne S, Mullikin JC, Mungall A, Plumb R, Ross M, Shownkeen R, Sims S, Waterston RH, Wilson RK, Hillier LW, McPherson JD, Marra MA, Mardis ER, Fulton LA, Chinwalla AT, Pepin KH, Gish WR, Chissoe SL, Wendl MC, Delehaunty KD, Miner TL, Delehaunty A, Kramer JB, Cook LL, Fulton RS, Johnson DL, Minx PJ, Clifton SW, Hawkins T, Branscomb E, Predki P, Richardson P, Wenning S, Slezak T, Doggett N, Cheng JF, Olsen A, Lucas S, Elkin C, ; International Human Genome Sequencing Consortium: Initial sequencing and analysis of the human genome. Nature 409(6822): 860-921, 2001. (Pubitemid 32165345)
21. Kazazian HH Jr.: Mobile elements: Drivers of genome evolution. Science 303(5664): 1626-1632, 2004.
22. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V and Mutirangura A: Distinctive pattern of LINE1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 23(54): 8841-8846, 2004. (Pubitemid 39593298)
23. Symer DE, Connelly C, Szak ST, Caputo EM, Cost GJ, Parmigiani G and Boeke JD. Human l1 retrotransposition is associated with genetic instability in vivo. Cell 110(3): 327-338, 2002.
24. Kazazian HH, Jr and Goodier JL: LINE drive. retrotransposition and genome instability. Cell 110(3): 277-280, 2002.
25. Estécio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, Jelinek J, Yang AS, Yan PS, Huang TH, Tajara EH and Issa JP: LINE1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2(5): e399, 2007.
26. Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE and Issa JP: CpG island methylation profiling in human melanoma cell lines. Melanoma Res 19(3): 146-155, 2009.
27. Dumortier J, Ratineau C, Scoazec JY, Pourreyron C, Anderson W, Jacquier MF, Blanc M, Bernard C, Bellaton C, Remy L, Chayvialle JA and Roche C: Site-specific epithelial mesenchymal interactions in digestive neuroendocrine tumours. An experimental in vivo and in vitro study. Am J Pathol 156(2): 671-683, 2000. (Pubitemid 30643822)
28. Niederle MB, Hackl M, Kaserer K and Niederle B: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 17 (4): 909-918, 2010.
29. Cernaianu G, Tannapfel A, Nounla J, Gonzalez-Vasquez R, Wiesel T and Tröbs RB: Appendiceal carcinoid tumour with lymph node metastasis in a child: case report and review of the literature. J Pediatr Surg 45(11): e1-5, 2010.
30. Burkitt MD, Pritchard DM: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 24 (9): 1305- 20, 2006.
31. Rindi G: The ENETS guidelines: The new TNM classification system. Tumori 96(5): 806-809, 2010.
32. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz- Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent- Viñuelas M, Monleon A and Salazar R: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumours (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9): 1794-803, 2010.
33. Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, Hamilton SR and Rashid A: Comparison of genetic alterations in neuroendocrine tumours: Frequent loss of chromosome 18 in ileal carcinoid tumours. Mod Pathol 18(8): 1079-1087, 2005. (Pubitemid 41224498)
34. Matsuzaki K, Deng G, Tanaka H, Kakar S, Miura S and Kim YS: The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res 11(24 Pt1): 8564-8569, 2005. (Pubitemid 43005901)
35. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M and Fuchs CS: 18q Loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 7: 72, 2007.
36. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, Buchardt M, Seifert HH and Visakorpi T: Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35(1): 58-65, 2002. (Pubitemid 34847869)
37. Sadikovic B, Al-Romaih K, Squire JA and Zielenska M: Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 9(6): 394-408, 2008.
38. Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet 7(1): 21-33, 2006. (Pubitemid 41828945)
39. Lotem J and Sachs L: Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 25 (59): 7663-7672, 2006. (Pubitemid 44967961)
40. Rodenhiser DI: Epigenetic contributions to cancer metastasis. Clin Exp Metastasis 26(1): 5-18, 2009.